UroToday1d
ASCO GU 2025: Prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial: Final Results
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a renal cell and testicular ...
UroToday1d
ASCO GU 2025: Evaluating Survival in Aggressive Variant Prostate Cancer Patients Undergoing PSMA Radioligand Therapy
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...
UroToday2d
ASCO GU 2025: The Impact of Salvage Therapies: Functional Outcomes and Quality of Life
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday2d
ASCO GU 2025: PSMA-Based PET Imaging in Newly Diagnosed, High-Risk Localized Prostate Cancer, a National Cancer Institute Cancer Moonshot Trial.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
UroToday2d
ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates
(UroToday.com) The 2025 GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with ...
UroToday2d
ASCO GU 2025: Modeling Survival Outcomes of KEYNOTE-564 with Standard of Care Control Arm Treatment: A Simulation Study
(UroToday.com) The 2025 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Fady Ghali discussing a simulation study of modeling survival outcomes of KEYNOTE-564 with ...
UroToday2d
ASCO GU 2025: Decipher Risk Stratification of Radiorecurrent Prostate Cancer: Correlative Analysis of the F-SHARP Trial of Salvage Reirradiation
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Abhishek Solanki discussing Decipher risk stratification of radiorecurrent prostate cancer, ...
UroToday3d
ASCO GU 2025: Long-Term Safety Outcomes of 177Lu‑PSMA-617 in Patients with Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Trials in ...
UroToday3d
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday5d
SUO 2019: Evaluation of Biomarkers 4K Score, SelectMDx and ExoDx™, PSAD, TRUS and MRI for the Detection of High-Grade Prostate Cancer
Washington, DC (UroToday.com) While PSA screening has resulted in decreasing prostate cancer mortality, PSA is also known to be a poorly specific test for the detection of clinically significant ...
UroToday5d
ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
UroToday5d
ASCO GU 2025: Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191)
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Rapid Oral Abstract Session C: Renal Cell Cancer. Dr.